We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-8.99%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$798M
AUM Growth
-$110M
Cap. Flow
-$2.61M
Cap. Flow %
-0.33%
Top 10 Hldgs %
29.72%
Holding
97
New
9
Increased
24
Reduced
42
Closed
4

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
MRK icon
Merck
MRK
+$18.1M
3
ABBV icon
AbbVie
ABBV
+$11.7M
4
NKTR icon
Nektar Therapeutics
NKTR
+$11.6M
5
ESPR
Esperion Therapeutics
ESPR
+$9.66M

Top Sells

Rank Stock Value
1
HBNC icon
Horizon Bancorp
HBNC
+$26.2M
2
HUM icon
Humana
HUM
+$12.6M
3
INCY icon
Incyte
INCY
+$8.5M
4
ELV icon
Elevance Health
ELV
+$8.22M
5
HCA icon
HCA Healthcare
HCA
+$7.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.7%
2 Industrials 0.42%
3 Technology 0.13%
4 Financials 0.1%
5 Energy 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$121B
$31.5M 3.95%
186,000
+768
+0.4% +$136K
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$27.9M 3.5%
+1,025,000
New +$26.5M
NVCR icon
3
NovoCure
NVCR
$1.73B
$25.4M 3.19%
340,000
-25,899
-7% -$2.07M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$24.2M 3.04%
247,303
+44,286
+22% +$4.99M
ESPR
5
DELISTED
Esperion Therapeutics
ESPR
$24M 3.01%
655,854
+243,761
+59% +$9.66M
NKTR icon
6
Nektar Therapeutics
NKTR
$2.39B
$21.9M 2.74%
80,000
+31,667
+66% +$11.6M
ABMD
7
DELISTED
Abiomed Inc
ABMD
$21.3M 2.68%
120,000
+27,100
+29% +$5.86M
BMY icon
8
Bristol-Myers Squibb
BMY
$133B
$21M 2.64%
415,000
+76,614
+23% +$3.6M
MDT icon
9
Medtronic
MDT
$109B
$20.1M 2.52%
185,218
+22,335
+14% +$2.33M
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.6B
$19.6M 2.45%
290,491
+9,142
+3% +$704K
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.9B
$19.2M 2.41%
150,000
-37,171
-20% -$4.98M
CVS icon
12
CVS Health
CVS
$133B
$19.2M 2.4%
303,768
-40,000
-12% -$2.37M
ABT icon
13
Abbott
ABT
$183B
$18.4M 2.31%
220,114
-39,438
-15% -$3.35M
MRK icon
14
Merck
MRK
$322B
$18.1M 2.27%
+225,320
New +$18.1M
LLY icon
15
Eli Lilly
LLY
$1.02T
$16.8M 2.1%
150,000
-10,000
-6% -$1.11M
UNH icon
16
UnitedHealth
UNH
$376B
$16.7M 2.1%
77,000
-28,000
-27% -$6.76M
BDX icon
17
Becton Dickinson
BDX
$45.6B
$15.9M 2%
64,575
-17,425
-21% -$4.3M
HUM icon
18
Humana
HUM
$43.7B
$15.3M 1.92%
60,000
-45,000
-43% -$12.6M
BSX icon
19
Boston Scientific
BSX
$69.5B
$15.1M 1.89%
370,000
-17,908
-5% -$759K
ELV icon
20
Elevance Health
ELV
$81.5B
$14.4M 1.81%
60,000
-30,000
-33% -$8.22M
GKOS icon
21
Glaukos
GKOS
$9.83B
$14.4M 1.8%
229,600
-6,311
-3% -$444K
NBIX icon
22
Neurocrine Biosciences
NBIX
$16.8B
$13.5M 1.69%
149,600
-30,400
-17% -$2.84M
ABBV icon
23
AbbVie
ABBV
$443B
$12.9M 1.61%
+170,000
New +$11.7M
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
$12.7M 1.59%
148,700
+13,326
+10% +$977K
REGN icon
25
Regeneron Pharmaceuticals
REGN
$78.5B
$12.5M 1.57%
45,031
+17
+0% +$5.03K
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2019 Portfolio in Review

As of Q3 2019, Rhenman & Partners Asset Management held 97 positions worth $798M, down 12% from $908M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q3 2019 filing shows 9 new, 24 increased, 42 reduced and 4 closed positions. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,025,000 shares worth $27.9M. The largest sale was Horizon Bancorp, an estimated $26.2M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q3 2019 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,025,000 shares worth $27.9M.
  • Rhenman & Partners Asset Management added most to Nektar Therapeutics in Q3 2019, an estimated $11.6M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2019 reduction was Humana, cutting an estimated $12.6M.
  • Rhenman & Partners Asset Management fully exited Horizon Bancorp in Q3 2019, selling an estimated $26.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $798M portfolio in Q3 2019.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 4 in Q3 2019.
  • Rhenman & Partners Asset Management's portfolio value fell 12% quarter-over-quarter to $798M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.